Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Enzon Pharmaceuticals Inc (ENZN)’s Shares Rally After Special Cash Dividend Announcement

Page 1 of 2

The shares of Enzon Pharmaceuticals Inc (NASDAQ:ENZN) have rallied in excess of 16% in trading today after the company announced a special cash dividend for its investors. The biotechnology company will pay the special dividend on August 12, 2015 to its shareholders of record on July 21, 2015. One of the most impressive facts about Enzon Pharmaceuticals is its return on assets, which stands at 88.70%. The biotechnology company announced three new directors in its annual shareholder meeting held on June 30, 2015. The Piscataway, New Jersey based company offers licensing for a huge portfolio of drugs including PegIntron for the treatment of chronic Hepatitis C, Macugen for macular degeneration associated with neovascular issues, Sylatron for melanoma, and CIMZIA for Crohn’s disease & rheumatoid arthritis.

cheerful pharmacist chemist woman standing in pharmacy drugstore

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) has witnessed a growth of 29.87% year-to-date and its shares are currently trading at $1.41. Smart money has held a steady outlook for the biotechnology firm of late, with eight hedge fund investors holding $9.81 million in the company on March 31 compared to previous investments of $9.89 million from nine investors one quarter earlier. It has notably attracted an investment from Carl Icahn, with Enzon Pharmaceuticals being one of the few small-cap investments of the legendary activist investor.

Carl Icahn
Carl Icahn
Icahn Capital LP

We don’t just track the latest moves of funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 2.5 years. The results of our analysis show that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests. Moreover, since the beginning of forward testing in August 2012, the strategy worked brilliantly, outperforming the market every year and returning 135%, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

In terms of insider activity, Enzon Pharmaceuticals Inc (NASDAQ:ENZN) has remained stable in the past six months. Keeping an eye on the insider activity provides an idea about the sentiment among insiders. For a better idea of the hedge fund activity going on in Enzon Pharmaceuticals, let’s analyze the recent action regarding its stock.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!